For instance, preclinical evidence indicates that ENPP1, secreted from primary breast cancer, can induce endothelial cell dysfunction by impairing insulin signaling and its downstream AKT/GSK3β/β-catenin pathway [106]. This evidence concerns the gene ENPP1 and breast cancer.